Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares were down 3.8% during trading on Tuesday . The stock traded as low as $13.61 and last traded at $13.61. Approximately 1,520 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 69,687 shares. The stock had previously closed at $14.15.
Gyre Therapeutics Trading Down 2.3 %
The company has a 50-day moving average price of $12.88 and a two-hundred day moving average price of $13.15.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 earnings per share (EPS) for the quarter. The company had revenue of $25.23 million during the quarter. On average, analysts forecast that Gyre Therapeutics, Inc. will post -0.45 earnings per share for the current year.
Hedge Funds Weigh In On Gyre Therapeutics
A number of hedge funds have recently modified their holdings of the business. Rhumbline Advisers acquired a new position in Gyre Therapeutics during the second quarter worth approximately $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the 2nd quarter worth approximately $166,000. Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics in the second quarter valued at $218,000. Finally, WINTON GROUP Ltd purchased a new position in shares of Gyre Therapeutics during the 2nd quarter worth approximately $220,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
